Gertrude Biomedical’s dedication to implementing transformational solutions for untreatable cancers will deliver succes via our drug development.

Our strategic approach, driving momentum towards the development of ‘big market’ SOX18 therapeutics, combined with our regulatory protection, offers a compelling investment opportunity.
We look forward to progressing partnering discussions for product collaborations and drug commercialisation. Any investor or partner enquiries can be directed to Gertrude via the contact us form.

Shareholder services

Shareholders can direct any queries regarding shareholdings or transactions via the Investor Relations Contact Us form